RFCS Projected Dividend Yield

Refocus Group Inc ( OTCBB : RFCS )

Refocus Group is a medical device company engaged in the research and development of treatments for eye disorders. Co. also uses its research and understanding of the human eye to develop and patent technology for use with commercial optical lens applications. Co.'s principal products are the patented PresVIEW Scleral Implant (the "PSI") and the PresVIEW Incision System, which consists of the surgical instruments used to implant the PSI in the surface of the white of the human eye. The PSI and PresVIEW Incision System are utilized in Co.'s surgical procedure, the Scleral Spacing Procedure, for the treatment of presbyopia, ocular hypertension and primary open angle glaucoma.

20 YEAR PERFORMANCE RESULTS